Biocytogen (HKEX: 02315) is thrilled to attend World ADC London 2025 at Novotel London West, UK, from March 3-6.

Dr. Benny (Yi) Yang, Chief Scientific Officer of Biocytogen, will deliver an insightful presentation, and our Business Development and Licensing Team will showcase two posters highlighting Biocytogen’s groundbreaking advancements in antibody-drug conjugate (ADC) projects. Don’t miss the chance to schedule a 1-on-1 meeting with us!

Presentation:

• Title: RenBiologics Accelerates the Development of Multi-Specific ADCs
• Date & Time: March 5th, 12:30-1:00 PM GMT

Poster Session

• Date & Time: March 5th, 10:30-11:30 AM GMT
• Location: Ground Floor, The Exhibition Space

Poster# 1: BCG027, a Novel SEZ6×B7H3 Bispecific ADC for the Treatment of Small Cell Lung Cancer

Poster# 2: 7E2, a First-in-Class Anti-Human ALPP/ALPG Therapeutic ADC That Inhibits Tumor Growth in Human Pancreatic Cancer and Gastric Cancer PDX Models

Biocytogen has independently developed the RenLite^® platform, which leverages common light chain technology to prevent mismatches between light and heavy chains during bispecific antibody assembly.

In addition, Biocytogen owns the proprietary Linker & Payload platform BLD1102. Utilizing RenLite and the new bispecific ADC platform, we have generated a large antibody library against more than 200 tumor-associated antigens (TAAs) and established over 400 antibody discovery projects.

We look forward to discussing licensing opportunities for new antibody molecules and antibody discovery platforms with you.

Please click here to schedule a 1-on-1 meeting with us to learn more.